- Avoid routine I.V administration due to the possibility of inducing sudden hypertensive and cerebrovascular accidents. If I.V administration is considered as a lifesaving measure, give slowly over at least 60 sec with careful monitoring of BP
- Avoid intra-arterial or periarterial injection
- Methylergonovine is contraindicated during pregnancy because of its uterotonic effects
- Mothers should not breastfeed during treatment and discard milk secreted during this period. Breastfeeding may be resumed at least 12 hrs after last dose. Therapy may produce adverse events in the breast-feeding infant and also decrease the yield of breast milk
- Inadvertent administration to newborn infants has reported with methylergonovine. Due to accidental neonatal exposure to methylergonovine it should be stored separately from medications intended for neonates
- Increased risk for myocardial ischemia and infarction in patients with coronary artery disease (CAD) associated with methylergonovine-induced vasospasm
Cautions: Use cautiously in
- Renal impairment
- Hepatic impairment
- Obliterative vascular disease
- Second stage of labor
- Sepsis
- Hypertensive patients
- Elderly patients
- Third stage of labor
Pregnancy Category:C
Breastfeeding: Limited information indicates that maternal doses up to 0.75 mg/day produce low levels in milk and would not be expected to cause any adverse effects in breastfed infants. However it can decrease serum prolactin and possibly suppress lactation, especially when used in the immediate postpartum period. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 5 May 2011). Manufacturer recommends use with caution in nursing woman.
US Trade Name(s)
US Availability
methylergonovine (generic)
- INJ: 0.2 mg/mL (1mL vials)
Methergine
- INJ: 0.2 mg/mL (1mL amps)
Canadian Trade Name(s)
Canadian Availability
UK Trade Name(s)
UK Availability
Australian Trade Name(s)
Australian Availability
[Outline]
